Patents by Inventor Ulrich Haupts
Ulrich Haupts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240091671Abstract: The present invention relates to Fc binding proteins comprising one or more domains with Cysteine in the C-terminal helical region. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.Type: ApplicationFiled: September 5, 2023Publication date: March 21, 2024Applicant: Repligen CorporationInventors: Erik Fiedler, Ulrich Haupts
-
Patent number: 11813336Abstract: The invention generally relates to targeted compounds for the site-specific coupling of chemical moieties. The present invention features a targeted compound for the coupling of chemical moieties comprising at least one targeting domain capable of binding a target, and at least one linking moiety of up to 80 amino acids, preferably alanine, proline, and serine, and at least one coupling site consisting of cysteine or a cysteine-rich peptide motif (CXC, CXXC, or CXXXC), and wherein said linking moiety connects the targeting domain and a coupling site and/or wherein a linking moiety connects two coupling sites. The invention further features fusion proteins with ubiquitin muteins (Affilin @) as targeting domain. The invention also relates to the use of the targeted compounds for medical applications, in treatment or diagnosis of diseases.Type: GrantFiled: May 4, 2017Date of Patent: November 14, 2023Assignee: Navigo Proteins GmbHInventors: Ulrich Haupts, Markus Liebscher, Erik Fiedler
-
Publication number: 20230340069Abstract: The present invention relates to Fc binding proteins comprising one or more domains with Cysteine in the C-terminal helical region. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.Type: ApplicationFiled: December 7, 2022Publication date: October 26, 2023Applicant: Repligen CorporationInventors: Erik Fiedler, Ulrich Haupts
-
Publication number: 20230322946Abstract: The present disclosure relates to new serum stable non-immunoglobulin binding proteins based on ubiquitin scaffold that are highly specific for membrane-bound receptor tyrosine kinase (Her2). The disclosure provides novel specific recombinant Her2 binding proteins with high serum stability essentially combined with high temperature stability and high affinity for Her2 for uses in medical applications for diagnosis or therapy of cancer with Her2 overexpression, in particular, for radiopharmaceutical applications.Type: ApplicationFiled: July 15, 2021Publication date: October 12, 2023Applicant: Navigo Proteins GmbHInventors: Eva Bosse-Doenecke, Manja Gloser-Bräunig, Ulrich Haupts
-
Patent number: 11779860Abstract: The present invention relates to Fc binding proteins comprising one or more domains with Cysteine in the C-terminal helical region. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.Type: GrantFiled: August 6, 2018Date of Patent: October 10, 2023Assignee: Repligen CorporationInventors: Erik Fiedler, Ulrich Haupts
-
Publication number: 20230295223Abstract: The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more domains having highly hydrophobic amino acids with branched side chains (Iso, Leu, Val), or aromatic amino acids (Tyr, Phe, or Trp) corresponding to position 4 or 6 or 8 of the Ig binding protein of SEQ ID NO: 1 or functionally similar proteins. The novel proteins have superior properties for highly efficient purification methods for antibodies (immunoglobulins), for example, the proteins have high binding capacity and high chemical stability. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.Type: ApplicationFiled: July 14, 2021Publication date: September 21, 2023Applicant: Navigo Proteins GmbHInventors: Paul Knick, Hanna Bobolowski, Mathias Kahl, Erik Fiedler, Ulrich Haupts
-
Publication number: 20230212218Abstract: The present invention relates to novel engineered artificial immunoglobulin (Ig) binding polypeptides comprising three domains and two linkers. The invention further relates to affinity matrices comprising these artificial Ig binding molecules of the invention. The novel Ig binding proteins are particularly useful for the affinity purification of proteins requiring elution at a higher pH (in particular higher than pH 4.2). The invention also relates to a use of the novel Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the novel Ig binding proteins of the invention.Type: ApplicationFiled: March 5, 2021Publication date: July 6, 2023Applicant: Navigo Proteins GmbHInventors: Hanna Bobolowski, Erik Fiedler, Ulrich Haupts
-
Patent number: 11548929Abstract: The present invention relates to Fc binding proteins comprising one or more domains with Cysteine in the C-terminal helical region. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.Type: GrantFiled: January 28, 2019Date of Patent: January 10, 2023Assignee: Repligen CorporationInventors: Erik Fiedler, Ulrich Haupts
-
Patent number: 11414466Abstract: The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.Type: GrantFiled: November 5, 2018Date of Patent: August 16, 2022Assignee: Navigo Proteins GmbHInventors: Erik Fiedler, Ulrich Haupts, Anja Katzschmann, Eva Bosse-Doenecke, Manja Gloser
-
Publication number: 20220168386Abstract: The present invention relates to new binding proteins that are specific for prostate specific membrane antigen (PSMA). The invention further refers to PSMA binding proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PSMA binding proteins in medicine, for example, in diagnosis and therapy of cancer associated with PSMA expression.Type: ApplicationFiled: April 8, 2020Publication date: June 2, 2022Applicant: Navigo Proteins GmbHInventors: Eva Bosse-Doenecke, Manja Gloser-Bräunig, Florian Settele, Erik Fiedler, Ulrich Haupts
-
Publication number: 20220127312Abstract: The present invention relates to new binding proteins that are specific for folate receptor alpha (FOLR1). The invention further refers to FOLR1 binding proteins that further comprises a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these FOLR1 binding proteins in medicine, for example, in diagnosis and therapy of FOLR1 related cancer.Type: ApplicationFiled: December 17, 2019Publication date: April 28, 2022Applicant: Navigo Proteins GmbHInventors: Erik Fiedler, Ulrich Haupts, Manja Gloser-Bräunig, Eva Bosse-Doenecke
-
Publication number: 20220073564Abstract: The present invention relates to the field of protein engineering and purification and relates in particular to novel polypeptides having a triple-helical structure and lacking binding affinity for the Fc domain of immunoglobulin. The invention further relates to uses of the novel non-Fc binding polypeptides in technical applications such as affinity chromatography, as well as in therapy and diagnostics. In addition, the present invention relates to a method of reducing the binding affinity of a polypeptide having a triple-helical structure for the Fc domain of immunoglobulin.Type: ApplicationFiled: November 12, 2019Publication date: March 10, 2022Applicant: Navigo Proteins GmbHInventors: Erik Fiedler, Ulrich Haupts, Madlen Zwarg
-
Patent number: 11230576Abstract: The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.Type: GrantFiled: August 7, 2017Date of Patent: January 25, 2022Assignee: Navigo Proteins GmbHInventors: Paul Knick, Erik Fiedler, Ulrich Haupts, Maren Meysing
-
Patent number: 11208436Abstract: Provided are populations of polypeptides, wherein each member of the population of polypeptides includes or is an amino sequence as set forth in SEQ ID NO: 5 or SEQ ID NO: 6. Also provided are methods for identifying polypeptides that bind to pre-selected target molecules, which in some embodiments can include providing a population of polypeptides as described herein, contacting the population of polypeptides with a pre-selected target molecule, and identifying a complex comprising at least one member of the population of polypeptides bound to the pre-selected target molecule; and populations of nucleic acid molecules that encode the presently disclosed populations of polypeptides.Type: GrantFiled: November 12, 2019Date of Patent: December 28, 2021Assignee: Navigo Proteins GmbHInventors: Erik Fiedler, Ulrich Haupts, Madlen Zwarg
-
Publication number: 20210206815Abstract: The present invention relates to Fc binding proteins comprising one or more Fc binding domains wherein at least one domain comprises of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-6 or 21. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.Type: ApplicationFiled: March 23, 2021Publication date: July 8, 2021Applicant: Repligen CorporationInventors: Paul Knick, Erik Fiedler, Ulrich Haupts, Maren Meysing
-
Publication number: 20210179678Abstract: The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.Type: ApplicationFiled: November 5, 2018Publication date: June 17, 2021Applicant: Navigo Proteins GmbHInventors: Erik Fiedler, Ulrich Haupts, Anja Katzschmann, Eva Bosse-Doenecke, Manja Gloser
-
Patent number: 11014967Abstract: The present invention relates to Fc binding proteins comprising one or more Fc binding domains wherein at least one domain comprises of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-6 or 21. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.Type: GrantFiled: August 7, 2017Date of Patent: May 25, 2021Assignee: Repligen CorporationInventors: Paul Knick, Erik Fiedler, Ulrich Haupts, Maren Meysing
-
Publication number: 20210054044Abstract: The present invention relates to Fc binding proteins comprising one or more domains with Cysteine in the C-terminal helical region. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.Type: ApplicationFiled: January 28, 2019Publication date: February 25, 2021Applicant: Repligen CorporationInventors: Erik Fiedler, Ulrich Haupts
-
Patent number: 10858405Abstract: The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin®), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.Type: GrantFiled: February 4, 2016Date of Patent: December 8, 2020Assignee: Navigo Proteins GmbHInventors: Eva Bosse-Doenecke, Florian Settele, Erik Fiedler, Ulrich Haupts
-
Patent number: 10808042Abstract: The present disclosure relates to non-natural binding proteins comprising one or more non-natural immunoglobulin (Ig) binding domains wherein at least one non-natural lg-binding domain comprises the amino acid sequence X1 X2X3XiXsX5X7 XsQQX11AFYX1sX15LX1 sX19PX21 LX23X24X2sQRX28X2gf IQSLKDDPSXio SXi2Xi3Xi4LXi5EAXigKLXs2Xs3Xs4QXs5PX. The disclosure also relates to compositions such as affinity matrices comprising the non-natural Ig-binding proteins of the invention. Use of these Ig-binding proteins or of the compositions for affinity purification of immunoglobulins and to methods of affinity purification.Type: GrantFiled: July 14, 2016Date of Patent: October 20, 2020Assignee: Navigo Proteins GmbHInventor: Ulrich Haupts